Trends in the Cost and Utilization of Omalizumab in the Medicare Population: 2013-2017

Background: Omalizumab has been demonstrated to be effective in treating chronic spontaneous urticaria (CSU) and was FDA approved for this indication in 2014. Previous work has shown that access to injectable biologics varies across US counties. In the present study we evaluate geographic and tempor...

Descripción completa

Detalles Bibliográficos
Autores principales: Cheraghlou, Shayan, Ugwu, Nelson, Yu, Beverly, Cohen, Jeffrey M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: YJBM 2022
Materias:
Brief Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9235260/
https://www.ncbi.nlm.nih.gov/pubmed/35782473

Ejemplares similares

Ejemplares similares